Content
12/17/2020
Carlsbad, CA USA
Carlsmed
completed $10 million Series A Round funding. Investors include
USVP (lead), Cove Fund, The Vertical Group, Wavemaker 360 Health.
About
Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery . The company’s aprevo® devices are designed to improve the standard of care for surgical treatment of patients with adult spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create optimal surgical plans and personalized aprevo® spine fusion devices for each patient. The Carlsmed® aprevo® devices are FDA cleared and have been granted FDA Breakthrough Designation, an industry first for any implanted device, and are commercially available in the U.S.
Startup
Sector:
MedTech
Healthcare
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
